Moderna receives fda authorization for emergency use of omicron-targeting bivalent covid-19 booster vaccine for children and adolescents 6 to 17 years of age

Mrna-1273.222 targets the ba.4/ba.5 strains of omicron variant authorization is based upon clinical and pre-clinical data for moderna's bivalent vaccine candidates cambridge, ma / accesswire / october 12, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that it has received emergency use authorization (eua) from the u.s. food and drug administration (fda) for its ba.4/ba.5 omicron-targeting bivalent covid-19 booster vaccine, mrna-1273.222, in children and adolescents 6 to 17 years of age. the authorizations are based on a 25 Μg booster dose for children ages 6 to 11 years old and a 50 Μg booster dose for adolescents 12 to 17 years old, each following a completed primary series of any of the authorized covid-19 vaccines or a previous booster.
MRNA Ratings Summary
MRNA Quant Ranking